DUBLIN, Ireland, April 25, 2013 /PRNewswire/ --
Research and Markets has announced the addition of the "PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013" report to their offering.
Sun Shines on Indian Generics Manufacturers
India is becoming a key market for generic medicines, and pharmaceutical companies must compete and grow their revenues there to have a shot at claiming the title of industry leader, according to a new report by research and consulting firm The authors.
Generic Manufacturers Benchmark Report states that India-based trio of Glenmark, Sun Pharmaceuticals, and Ranbaxy topped the charts in terms of year to year (YTY) revenue growth in 2012, with 71.6%, 47.6%, and 32.9% respectively. Although larger generic manufacturers - Teva, Sandoz, and Mylan - emerged as revenue leaders in 2012, with sales of US$10.4 billion, US$8.7 billion, and US$5.8 billion respectively, their performance in 2013 may vary, as other competitors, including Sun Pharmaceuticals step up efforts to grow their share of the global generics market.
Domestic players in India are currently experiencing massive growth YTY revenue as they continue to leverage many decades of reverse engineering experience. The authors believes that Indian generic manufacturers have become the go-to companies when it comes to low-cost generics, as affirmed by the entrance of pharmaceutical giants such as Gilead and Pfizer into generic manufacturing agreements with them in 2012.
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved